https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

ASCO 2025: Stratifying NSCLC Treatment by HER2-Alteration Subtype

ASCO 2025: Stratifying NSCLC Treatment by HER2-Alteration Subtype

Nikita Dahake, MD; Hossein Borghaei, DO, MS; and Yasmine Baca, MS, PhD candidate, MB(ASCP)CM, explore how distinct HER2-alteration subtypes in non-small cell lung cancer (NSCLC) impact survival outcomes, co-mutation profiles, and treatment response to immunotherapy-based regimens.

administrator

Related Articles